Compare Merck & Co., Inc. (MRK) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Wheaton Precious Metals Corp — how do they compare? Merck & Co., Inc. trades at $148.25 (market cap $366.28B), while Wheaton Precious Metals Corp trades at $156 (market cap $70.35B). The key difference: Merck & Co., Inc. is far larger — about 5.2× Wheaton Precious Metals Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | WPM | |
|---|---|---|
Market Cap | $366.28B | $70.35B |
Sector | Health | Basic Materials |
52-Week High | $156.43 | $165.72 |
52-Week Low | $77.60 | $94.37 |
Enterprise Value | $413.04B | $72.23B |
Dividend Yield | 2.29% | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Wheaton Precious Metals (WPM) trades at $155.11, up 0.08% with a bullish technical outlook and strong institutional support. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.19 beating expectations of $1.15. Revenue surged to $2.31 billion in 2025 with exceptional 64.66% net margins, while cash flow from operations reached $1.90 billion. Analysts maintain 80% buy ratings with a $161.75 consensus target, representing 4.3% upside potential.
WPM's streaming model provides leveraged exposure to precious metals without mining operational risks, supported by fully-funded growth pipeline targeting 50% production increase by 2030. Key risks include commodity price volatility and execution of the ambitious $5.1 billion 2026 investment plan. The stock offers growth potential but requires monitoring of gold/silver price trends and capital deployment efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
